Login / Signup

First-line treatment options for advanced non-small cell lung cancer patients with PD-L1 ≥ 50%: a systematic review and network meta-analysis.

Mingfeng HeTaihao ZhengXiaoyue ZhangYuan PengXuan JiangYusheng HuangBenxu TanZhen Zhou Yang
Published in: Cancer immunology, immunotherapy : CII (2021)
The study suggested that chemotherapy plus ICIs might improve PFS and ORR than single-agent ICIs for advanced NSCLC patients with PD-L1 ≥ 50%. However, it did not lead to OS benefit.
Keyphrases
  • advanced non small cell lung cancer
  • epidermal growth factor receptor
  • small cell lung cancer
  • locally advanced